How does the blood-brain barrier actually stop drugs?
The blood-brain barrier is a tightly packed layer of endothelial cells lining the brain's blood vessels. These cells are connected by what are called tight junctions—essentially molecular zippers—that prevent almost all substances from slipping between them [3][5]. Only very small, fat-soluble molecules (like oxygen and some anesthetics) can pass through the cell membranes directly; most drugs are too large or the wrong chemical type to get through [5]. This means that for the vast majority of therapeutic molecules—including antibodies, gene therapies, and many standard chemotherapy drugs—the BBB is an almost impenetrable wall [9].
The barrier is so effective that it blocks more than 98% of small-molecule drugs and essentially all large-molecule drugs from entering the brain [3][9]. This is not a flaw—it evolved to protect the brain from toxins and pathogens in the blood. But it creates a huge problem for treating brain tumors, Alzheimer's, Parkinson's, multiple sclerosis, and other central nervous system disorders [2][5]. As one review put it, the BBB 'complicates the pharmacotherapy for CNS disorders as the most chemical drugs and biopharmaceuticals have been impeded to enter the brain' [3].
What strategies are actually working to get drugs past the BBB?
Researchers have developed several promising approaches, and the most advanced ones work by either temporarily opening the barrier or by hijacking the brain's own transport systems. Focused ultrasound is a non-invasive technique that uses sound waves to briefly and safely open the BBB in a targeted area, allowing drugs to enter [1][10]. Another approach uses 'peptide shuttles'—short protein fragments that can latch onto natural transport receptors on the BBB, like the transferrin receptor, and carry a drug cargo across via a process called receptor-mediated transcytosis [7][9]. This is the same mechanism the brain uses to bring in essential nutrients like iron.
Nanoparticles are another major area of progress. These are tiny particles—often made of polymers, lipids, or gold—that can be engineered to carry drugs and decorated with targeting molecules on their surface [4][11]. For example, one study found that gold nanoparticles coated with transferrin (a protein that binds to the transferrin receptor) showed the strongest ability to cross the BBB in a lab model, while bare nanoparticles of the same size barely got through [8]. The key is that the nanoparticle's size, surface coating, and targeting ligand all matter: 13-nanometer transferrin-coated particles worked best, while 80- and 120-nanometer uncoated particles caused barrier damage and penetrated poorly [8].
What are the limitations and risks of these approaches?
Despite the progress, no single strategy is a magic bullet. Many of these techniques are still in early clinical testing, and each has trade-offs. Focused ultrasound, for instance, requires specialized equipment and can only open the BBB temporarily—the window for drug delivery is limited to a few hours [1]. Nanoparticle-based delivery faces challenges with manufacturing consistency, potential toxicity, and the fact that the body's immune system may clear the nanoparticles before they reach the brain [4][11]. Even receptor-mediated transcytosis can be inefficient: the drug cargo may get trapped inside the brain's endothelial cells (in lysosomes) instead of being released into the brain tissue, or the number of available receptors may be too low to carry a therapeutic dose [6].
Another complication is that the BBB itself changes in disease. In conditions like stroke, multiple sclerosis, and some brain tumors, the barrier can become leaky, which might seem like an advantage for drug delivery [5]. But this leakiness is unpredictable and can let in harmful substances along with the drug, potentially causing inflammation or brain swelling [5]. The bottom line is that while the BBB is a formidable barrier, it is not insurmountable—but getting drugs across safely and effectively requires matching the right delivery strategy to the specific disease and drug, and that is still an active area of research [1][9][10].
Sources used in this answer
Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma
The blood-brain barrier and tumor microenvironment are major obstacles for glioblastoma treatment; strategies like focused ultrasound, nanoparticles, and antibody-drug conjugates are being developed to overcome them.
Drug Delivery Across the Blood–Brain Barrier: A New Strategy for the Treatment of Neurological Diseases
The BBB's physiological properties greatly limit CNS drug delivery; physical, biological, chemical, and nanoparticle-based approaches are reviewed for overcoming this.
The blood–brain barrier: Structure, regulation and drug delivery
The BBB blocks over 98% of small-molecule drugs and nearly all biopharmaceuticals; emerging strategies include passive transcytosis, intranasal delivery, ligand conjugation, and stimuli-triggered disruption.
Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology
Nanoparticles (polymeric, liposomal, gold, dendrimers, etc.) can improve drug transport to brain tumors via paracellular transport, carrier-mediated transport, and transcytosis.
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
The BBB is a diffusion barrier that only tiny molecules can cross; in diseases like stroke and Alzheimer's, the barrier can become leaky, which may be exploited for drug delivery.
Promoting Drug Delivery to the Brain by Modulating the Transcytosis Process across the Blood-Brain Barrier.
A hybrid cell membrane-coated nanocarrier that uses membrane fusion to bypass endocytosis and enhance exocytosis achieved significantly improved delivery of a photothermal agent (CuS) to brain glioma in a model.
Peptide Shuttles for Blood–Brain Barrier Drug Delivery
Peptide shuttles can target natural transport mechanisms of the BBB (e.g., receptor-mediated transcytosis) to increase delivery of drugs that cannot cross unaided.
Understanding drug nanocarrier and blood–brain barrier interaction based on a microfluidic microphysiological model
Using a microfluidic BBB model, transferrin-coated 13 nm gold nanoparticles showed the strongest BBB penetration and least barrier disruption, while larger bare nanoparticles (80–120 nm) caused dysfunction.
Strategies for delivering therapeutics across the blood–brain barrier
Receptor-mediated transcytosis, neurotropic viruses, nanoparticles, and exosomes are among the non-invasive strategies being evaluated for CNS drug delivery, some in clinical trials.
Overcoming the Blood-Brain Barrier for Drug Delivery to the Brain.
Strategies include localized delivery (convection-enhanced, implants), encapsulation in vectors (viral, exosomes, nanoparticles), and BBB modulation (focused ultrasound, receptor-mediated delivery).
Nanotechnology in Drug Delivery: An Overview of Developing the Blood Brain Barrier.
Nanoparticles (e.g., gold, polymeric) are used as nano-carriers for targeted brain drug delivery, offering advantages over conventional methods but also facing challenges in safety and efficacy.